The tests and tools to simplify the complex challenges of diagnosing autoimmune disorders

Diagnosing, treating, and managing your autoimmune patients requires a collaborative, team approach. Quest Diagnostics is proud to support rheumatologists and other specialty care providers with new innovative autoimmune tests that can help facilitate earlier detection for a more confident diagnosis of autoimmune diseases.

As an industry leader in diagnostic testing, our expansive menu includes routine labs as well as new, innovative esoteric panels and tests, clinical expertise in rheumatology, tools for improving practice efficiency, and services to keep your patients actively engaged in their health.

With Quest, our comprehensive test menu and services provide you a single source for all your testing needs. Relying on a single lab helps streamline practice workflow, enhance patient reporting, and potentially improve time to diagnosis and overall patient outcomes.

Early diagnosis and identification of autoimmune disorders means you can start your patients’ therapy sooner, which may lead to remission with no active inflammation or functional deterioration.1

Innovative new tests can lead to earlier diagnosis

From screening to prognosis to monitoring, we support your practice with a full range of autoimmune disease panels and tests. Some of our newest tests include:

ANAlyzer ANA IFA with Reflex Titer/Pattern Systemic Autoimmune Panel – TC 36378

This ANA Screen, Immunofluorescence assay (IFA), Reflex Titer/Pattern panel evaluates 25 analytes from a single sample to provide clear, positive identification of specific antibodies for the most common autoimmune rheumatic diseases.

The new panel:

  • Utilizes IFA with HEp-2 cells, which remains the gold standard3
  • Provides greater specificity through IFA testing as compared to dsDNA
  • Tests for all analytes regardless of ANA results
  • Tests for rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), Sjögren’s syndrome, systemic sclerosis (SSc), polymyositis/ dermatomyositis, CREST syndrome, and neuropsychiatric SLE

Visit Test Directory

Antinuclear Autoantibody (ANA) Screen with Reflexes – TC 94954

The ANA Screen, IFA, Reflex Titer/Pattern, Reflex Mplx 11 Ab Cascade with IdentRA® from Quest Diagnostics provides clear, positive identification of specific antibodies for the 8 most common rheumatic diseases with one blood draw.

Our new panel:

  • Utilizes IFA with HEp-2 cells, which remain the gold standard3
  • Reflexes to tiered cascading of specific autoantibodies to maximize sensitivity and specificity
  • Tests for rheumatoid arthritis (RA), systemiclupus erythematosus (SLE), mixed connective tissue disease (MCTD), Sjögren’s syndrome, systemic sclerosis (SSc), polymyositis/dermatomyositis, CREST syndrome, and neuropsychiatric SLE

Visit Test Directory

Anti-Synthetase Panel 1 – TC 38075

This semi-quantitative line blot assay assesses myositis-specific antibodies to aid in the diagnosis of anti-synthetase syndrome. Antibodies include: Jo-1, EJ, OJ, PL-7, PL-12.

Visit Test Directory

Myositis Specific 11 Antibodies Panel – TC 94777

This test helps to provide a more confident diagnosis of polymyositis/dermatomyositis (PM/DM). The autoantibodies include: Jo-1, EJ, OJ, PL-7, PL-12, SRP, Mi-2α, Mi-2β, MDA-5, NXP-2, TIF-1γ.

Visit Test Directory

Systemic Sclerosis (Scleroderma) 12 Antibodies Panel 2 – TC 94685

The Systemic Sclerosis (SSc) 12 Antibodies Panel 2 looks at several antibodies that are highly specific for SSc, including: Scl-70, CENP-A, CENP-B, RP11, RP155, U1-snRNP RNP A, U1-snRNP RNP C, U1-snRNP RNP-70kd, Fibrillarin, Th/To, PM/Scl-100, PM/Scl-75.

The panel:

  • Helps to provide a diagnosis of SSc
  • Helps physicians determine SSc type
  • Identifies organ involvement
  • Informs patient prognosis
  • Looks at antibodies that are present in overlap syndromes with SSc

Visit Test Directory

Pre-biologic/-biosimilar HCV, HBV, and TB, Screen Panel w/Reflexes – TC 37616/37620

The Pre-biologic panel from Quest Diagnostics includes American College of Rheumatology (ACR) and American College of Gastroenterology (ACG) guideline-recommended tests you need to evaluate your autoimmune patients prior to initiating therapy with biologics and/or biosimilars.

The panel includes tests for:

  • HBV screening
  • HCV screening
  • TB infection screening (interferon gamma release assay or IGRA)

Visit Test Directory

Adalimumab and Infliximab Testing – TC 36302, 36310, 36312, 36295, 36299, 36297

Quest Diagnostics offers a series of tests for TNF blockers for rheumatic diseases, including RA, plaque psoriasis, and psoriatic arthritis. These tests provide unique insights to enable rheumatologists to devise a tailored, personalized treatment strategy for each patient, including:

  • Measures level of drug and antibody to drug for RA
  • Identifying primary or secondary failure of TNF blockers
  • Adjusting dose or dosing intervals
  • Switching to a different TNF blocker
  • Switching to a non-TNF blocker

Visit Adalimumab Tests Visit Infliximab Tests

HLA-B*58:01 Typing – TC 93932

This test helps evaluate risk of severe cutaneous adverse reactions (SCARs) to allopurinol, which is widely used to treat conditions associated with hyperuricemia such as uric acid kidney stones, uric acid neuropathy during chemotherapy, and gout.

Visit Test Directory

Expertise in specialty care to help you improve patient outcomes

When it comes to rheumatology, Quest Diagnostics provides an unparalleled level of insight, which can help you make more informed decisions.

  • More than 600 MDs, PhDs, and genetic counselors with expertise in immunology, infectious disease, and other sub-specialties for consultation on test selection and results interpretation
  • A comprehensive test menu for intersecting specialty care areas (eg, oncology, gastroenterology, dermatology, women’s health, neurology)
  • In-house testing services to enable faster turnaround time

Tools for improving efficiency in your practice

As a rheumatologist, you often need to coordinate care across multiple doctors and specialties. Our broad array of integrated tools and services are designed to help you streamline the delivery of care, so you can spend less time on paperwork, and more time on the health of your patients.

  • Quanum™ for Healthcare Professionals: The QuestQuanum suite of health information technology solutions can help you streamline your practice workflow and save your staff valuable time
    • Quanum™ Lab Services Manager: With one login, on any device, Lab Services Manager enables you to easily manage all of your laboratory-related tasks from one easy-to-use convenient platform
    • Quanum™ Interactive Insights: By depicting lab results and trends over time in a graphic-rich display, Quanum Interactive Insights simplifies results reporting and helps you have more meaningful conversations with your patients
  • Seamless technology solutions: Quest is integrated with more than 650 EHRs—which can mean that lab results and relevant clinical information are always at your fingertips

Keeping patients engaged for better health outcomes

Quest is committed to helping you and your patients work together toward better health.

  • Broad, in-network access: Quest is in-network with most major health plans—and in some cases has achieved Preferred Lab Network status—which can mean lower out-of-pocket costs for your patients
  • 2,200 Patient Service Centers: It’s easy for your patients to get the tests they need at the times and places that are most convenient for them
  • Online appointment scheduling: Patients can schedule appointments online 24/7
  • MyQuest: Our patient portal and mobile app allow patients to get results any time, anywhere, share results with multiple providers, and schedule medication reminders
  • Patient advocacy: We create educational materials to inform and encourage patients to talk to their doctors about autoimmune diseases

Autoimmune testing resource center

As an industry leader in autoimmune testing, Quest provides a series of educational resources to help you make more informed decisions for your patients.

Select the topics you’re interested in, fill out the form, and click download.

Articles/white papers:



The Importance of Anti-Drug Antibodies in Patients
Receiving Biologic Therapies

Date: Tuesday, July 17, 2018
Author: Alan Epstein, MD
Clinical Professor of Medicine,
University of Pennsylvania School of Medicine

Contact us

Fill out the fields below to learn how Quest’s autoimmune testing portfolio can help illuminate timely insights to help you make more informed treatment decisions.

Content intended for health care professionals